SCHEMBL4358673

SCHEMBL4358673

N#Cc1ccc(NC(=O)Nc2cc(Cl)cc(Cl)c2O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
MAPT P10636 3/20 0.64
HTT P42858 3/20 0.64
NLRP3 Q96P20 2/20 0.64
TSHR P16473 1/20 0.64
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
MAPK1 P28482 1/20 0.51
RAB9A P51151 1/20 0.51
IL18 Q14116 1/20 0.51
CXCR1 P25024 1/20 0.51
CXCR2 P25025 1/20 0.51
TMPRSS4 Q9NRS4 1/20 0.50
GLA P06280 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348490 0.86 GRIK1 (0.59) LMNAMAPTHTTNLRP3MEN1
SCHEMBL4358449 0.84 MAPT (0.69) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4359567 0.83 MAPT (0.56) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4353243 0.82 MAPT (0.61) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4349313 0.82 MAPT (0.70) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4358279 0.81 MEN1 (0.63) LMNAMAPTHTTTSHRMEN1
SCHEMBL4355634 0.81 MAPT (0.56) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4345888 0.79 P2RY1 (0.56) LMNAMAPTHTTTSHRMEN1
SCHEMBL4116856 0.79 MAPT (1.00) LMNAMAPTHTTNLRP3TSHR
SCHEMBL4349059 0.78 GRIK1 (0.63) MAPTHTTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 LMNA 3160/4885MAPT 4439/4885HTT 3824/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 LMNA 3661/4885MAPT 4184/4885HTT 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.